Nixxi Health

Nixxi Launches the First Widely Available Digital Health Screening Tool for Preterm Birth

Nixxi’s PopNatal™ offers the earliest and most cost-effective identification of women at risk for premature delivery. PHOENIX (PRWEB) NOVEMBER 16, 2020 Nixxi, a women’s health company with a mission to improve pregnancies and pregnancy outcomes, announces the launch of PopNatal, a proprietary digital assessment of a woman’s risk for preterm birth. The current standard of care, which largely consists of history-based screening, misses 93% of women who will have a preterm delivery. Based on advanced technology developed by leading maternal-fetal medicine physicians and data scientists, PopNatal identifies nearly ten times more women at risk for preterm birth than current screening methods in early pregnancy. Early identification provides health care providers and women with the best opportunities to take proactive steps to reduce preterm birth risk. PopNatal is a clinical decision support tool that provides actionable intelligence to health care providers for patient management. PopNatal is immediately available to women, clinicians, and healthcare payors. How it Works A woman who is planning for a pregnancy, or upon learning she is pregnant, may register on the Nixxi website (http://www.nixxihealth.com) for access to PopNatal. She will be asked to provide information about herself and her health history within the secure and HIPAA-compliant portal. Nixxi then analyzes hundreds of data points using a proprietary algorithm in order to produce a risk assessment. Within 72 hours, Nixxi reports the results to the woman’s health care provider. The results allow the woman and her...

read more

Nixxi Developing Mass Spec Test Targeting Preterm Birth Space

We are pleased to share 360dx's profile of Nixxi. Our company is focused on creating clinical tools that address the most critical segment of premature births - those delivered prior to 32 weeks. Additionally, as reported, we are exploring solutions from another perspective - the ability to accurately predict neonatal outcomes early in pregnancy.

read more

Alterations in Endogenous Progesterone Metabolism Associated with Spontaneous Very Preterm Delivery

A peer-reviewed study from Nixxi, just published in Human Reproduction Open, demonstrates that measurement of two different steroid hormones in the blood of women early in pregnancy may be predictive for an increased risk for delivery prior to 32 weeks, which is classified as a very preterm delivery. Very preterm deliveries are associated with higher rates of complications, greater likelihood of long-term care needs, and greater costs to the healthcare system. The study is publicly accessible at: https://academic.oup.com/hropen/article/2020/2/hoaa007/5816056 Preterm birth is common and is an important source of long-term handicaps and mortality for newborns. Currently, there are limited tools available to identify which pregnant women will deliver prematurely. Identification of women at risk for preterm delivery is important to facilitate targeted treatment or enhanced care to decrease the likelihood of having a premature baby. Reviewing a woman’s obstetric history is the primary means by which providers have to screen an individual woman for risk of preterm delivery, as a prior spontaneous preterm delivery is an important risk factor. Despite this, the vast majority of preterm deliveries occur in women without a history of preterm birth. Spontaneous preterm birth is increasingly being recognized to represent a common end pathway for a number of different disease phenotypes that include infection, inflammation, premature rupture of the membranes, uterine over distension, cervical insufficiency, placental dysfunction and genetic predisposition. In addition to these...

read more

Follow Us

Join our mailing list to stay informed of Nixxi’s latest developments, including new products and opportunities to enhance your healthcare. You can unsubscribe at any time if desired.